Be Biopharma

Be Biopharma is a biotechnology company dedicated to pioneering Engineered B Cell Medicines (BCMs) to improve the lives of patients suffering from cancer, rare diseases, and other serious conditions. BCMs are a novel class of cellular therapies that utilize the body's own B cells, which are naturally equipped to produce proteins, to deliver continuous expression of therapeutic proteins. This approach holds the potential to offer more durable, re-dosable, and effective treatments compared to traditional therapies.

Be Biopharma was founded in 2020 by B cell engineering pioneers David Rawlings and Richard James from Seattle Children's Research Institute. The company is backed by a strong investor syndicate including ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, Takeda Ventures, Seattle Children's Research Institute, and others. With a dedicated team of scientists, technologists, manufacturing experts, and business builders, Be Biopharma is committed to developing innovative cell therapies that address unmet needs in a wide range of therapeutic areas.

Be Biopharma offers a "wise freedom" approach to work-life integration, prioritizing mental health and well-being. They offer a comprehensive benefits program to support team members and their families, allowing for a balance between work and personal life. This includes the ability to work hard and recharge, and the opportunity to bring passions to life within the company.

Be Biopharma offers a comprehensive benefits package designed to support employees and their families. This includes benefits for physical, mental, and financial well-being, prioritizing mental health and work-life balance. Employees are encouraged to work hard but also to take time to play hard and recharge, fostering a culture that values personal growth and a sense of community.

Be Biopharma is a biotechnology company dedicated to pioneering a new class of cell therapies, Engineered B Cell Medicines (BCMs), to dramatically improve the lives of patients living with serious diseases. They believe that by leveraging the inherent power of B cells as nature’s medicine factories, they can create durable, redosable, and allogeneic treatments for a wide range of diseases, including rare diseases, cancer, and other serious conditions.

Be Biopharma fosters a culture centered around purpose, passion, and character. They are dedicated to creating transformative medicines for patients and embrace the highest standards of transparency, excellence, and collaboration. The company is committed to providing a compelling and dynamic work experience for its employees, fostering growth, a sense of belonging, and support in both personal and professional lives. Be Bio is a team that works hard, plays hard, and supports each other on their shared journey to improve the lives of patients.

Be Biopharma is committed to fostering a culture of diversity, equity, and inclusion, recognizing that a range of perspectives and backgrounds strengthens their team and leads to better scientific outcomes. They actively pursue a diversity of ideas, interests, and backgrounds within their organization and the broader biotech industry, actively participating in the "We Rise Together" initiative, a leadership development program focused on promoting underrepresented talent populations in Boston's biotech sector.